ClinicalTrials.Veeva

Menu

Sulforaphane Supplementation in Atopic Asthmatics (brasma)

University of North Carolina (UNC) logo

University of North Carolina (UNC)

Status and phase

Completed
Phase 1

Conditions

Asthma

Treatments

Dietary Supplement: Alpha Sprout Homogenate
Dietary Supplement: Sulforaphane Homogenate

Study type

Interventional

Funder types

Other

Identifiers

NCT01845493
13-0056

Details and patient eligibility

About

The investigators will perform a pilot study of daily treatment with oral sulforaphane (SFN) for 3 days to determine if Nuclear factor (erythroid-derived 2)-like 2 (NRF2) induction is possible with this supplementation regimen in individuals with allergic asthma.

Full description

This pilot study will examine if oral SFN supplementation can induce NRF2 and NRF2-dependent phase II enzymes in nasal epithelial cells of allergic asthmatics. Subjects will receive both a SFN-rich broccosprout homogenate preparation and an alfalfa sprout homogenate (placebo) in a crossover fashion. mRNA levels of NRF2 and NRF2-dependent phase II enzymes will be compared between the active and placebo periods.

Enrollment

16 patients

Sex

All

Ages

18 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age 18-50 of both genders
  2. History of episodic wheezing, chest tightness, or shortness of breath after age of 6 years consistent with asthma, or physician diagnosed asthma after age of 6 years.
  3. AND: Positive methacholine test. A positive test is defined as a provocative concentration of methacholine of 10 mg/ml or less producing a 20% fall in FEV1 (PC20 methacholine). Methacholine challenge in a separate screening protocol (98-0799), or from other venues will be accepted.
  4. OR: Pre and post bronchodilator FEV1 improvement by 12% or more after 4 puffs of albuterol inhaler.
  5. FEV1 of at least 80% of predicted and FEV1/FVC ratio of at least .70 (without use of bronchodilating medications for 12 hours), consistent with lung function of persons with no more than mild episodic or mild persistent asthma (NHANES III predicted set).
  6. Allergic sensitization to at least one of the following allergen preparations: (House Dust Mite f, House dust mite p, Cockroach, Tree mix, Grass Mix, Weed Mix, Mold Mix 1, Mold Mix 2, Rat, Mouse, Guinea Pig, Rabbit, Cat or Dog) confirmed by positive immediate skin test response in a separate screening protocol. Proof of allergy from other venues, including ImmunoCAP testing from a medical workup, provided by the subject, will be accepted.
  7. Oxygen saturation of > 94 % and normal blood pressure (Systolic between 150 - 90, Diastolic between 90-60 mm Hg)
  8. Willing to provide information regarding health history and habits of cigarette smoke exposure;
  9. Willing to avoid antioxidant vitamins and cruciferous vegetables as well as juices/drinks with added vitamin supplements for 2 days prior the baseline screening visit and throughout initial dosing period.
  10. Subjects must be willing to avoid antihistamine use for 4 days prior to each session and NSAIDs for 7 days prior to each session. Nasal steroids must be held for 2 weeks prior to the session.

Exclusion criteria

  1. Medical history or underlying health problems that preclude participation in the protocol per the study physician;
  2. Current nutritional disorder such as anorexia, bulimia, irritable bowel syndrome, Crohn's disease etc;
  3. Use of oral corticosteroids within the past 4 weeks;
  4. Presence of upper or lower respiratory tract infection or treatment with antibiotics within the previous 4 weeks;
  5. Pregnancy as determined by menstrual history or urine pregnancy test;
  6. Current smokers will be excluded. Anyone with a smoking history > 0.5 pack year and/or >1 pack per month will also be excluded.
  7. History of bleeding disorder;
  8. Recent nasal surgery (with 6 months). If a subject has had nasal surgery between 6 months and 5 years, a study physician will visualize the area prior to the biopsy to evaluate the suitability of the nose for the procedure.
  9. History of intolerance of or aversion to broccoli
  10. Unable to withhold nasal steroids for 2 weeks before each session. These subjects may be deferred until after their allergy season.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

16 participants in 2 patient groups, including a placebo group

Sulforaphane-rich supplement
Active Comparator group
Description:
Intervention: broccosprout homogenate (rich in Sulforaphane) taken orally daily x 3 days
Treatment:
Dietary Supplement: Sulforaphane Homogenate
Alfalfa Sprout Homogenate
Placebo Comparator group
Description:
Placebo: Alfalfa sprout homogenate taken daily x 3 days (poor in sulforaphane)
Treatment:
Dietary Supplement: Alpha Sprout Homogenate

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems